Biotech firm Actelion’s flagship drug Tracleer, already approved for treating pulmonary arterial hypertension (PAH), can also help prevent digital ulcers in scleroderma patients, the firm said on Tuesday.
Should additional trials uphold the initial clinical findings, Tracleer could find wider usage among patients with the autoimmune rheumatic disease that in more than one out of four cases triggers painful open sores on the fingers or toes.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!